Hospira's Inflectra becomes Europe's first approved biosimilar monoclonal antibody


Celltrion and Hospira (HSP) get final approval from the European Commission for Inflectra.

The rheumatoid arthritis treatment is a biosimilar of Johnson & Johnson (JNJ) and Merck's (MRK) Remicade ($2B in European sales last year).

The news marks a biotech milestone: It's Europe's first biosimilar monoclonal antibody therapy.

HSP will launch the drug "at the earliest opportunity taking into account any relevant patent protection." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs